
Home / News
- 
- 

 - 
UK Company Starts Trials of Inhaled Formulation for COVID-192020-03-26View More
 
 - 
 - 
- 

 - 
Defects on the glass surface are a major cause of occasional breakage of the primary packaging container during fill and finish or transport.2020-03-26View More
 
 - 
 - 
- 

 - 
Following reports that hydroxychloroquine and chloroquine are under evaluation in clinical trials as a potential treatment of COVID-19, drug companies are donating doses and planning for ramping up supply.2020-03-26View More
 
 - 
 - 
- 

 - 
FDA, EMA Collaborate on SARS-CoV-2 Vaccine Development2020-03-26View More
 
 - 
 - 
- 

 - 
On March 23, 2020, Eli Lilly and Company provided an update on the company's clinical trial activities in light of the COVID-19 pandemic.2020-03-26View More
 
 - 
 - 
- 

 - 
BioM¨¦rieux said on Tuesday that an assay developed by its subsidiary BioFire Defense to rapidly detect COVID-192020-03-26View More
 
 - 
 - 
- 

 - 
Japanese Regulators Approve Merck KGaA MET Inhibitor With ArcherDx CDx2020-03-26View More
 
 - 
 - 
- 

 - 
The US Food and Drug Administration on Friday warned consumers to watch out for companies marketing unproven products for diagnosing, preventing, or treating COVID-19.2020-03-26View More
 
 - 
 - 
- 

 - 
While many in the US and Europe have only recently come to understand the scope and severity of the SARS-CoV-2 pandemic, a handful of proteomics labs have been studying the virus since the beginning of the year.2020-03-26View More
 
 - 
 - 
- 

 - 
A new UK-based research consortium is betting that sequencing the virus that causes COVID-19 can provide policymakers with a clearer picture of the spread of the epidemic across the country as diagnostic testing remains limited.2020-03-26View More
 
 - 
 - 
- 

 - 
In a new study published in Nature on Wednesday, researchers in China described the cell type composition of all major human organs, based on the RNA sequences of more than 500,000 single cells from Chinese Han donors.2020-03-26View More
 
 - 
 - 
- 

 - 
Personalis reported after the close of the market on Wednesday that its fourth quarter revenues rose 38 percent year over year2020-03-26View More
 
 - 
 - 
- 

 - 
Oncocyte said after the close of the market on Wednesday that its fourth quarter net loss rose 77 percent year over year as it pushed toward a transition to commercial test operations.2020-03-26View More
 
 - 
 - 
- 

 - 
Biocept said after the close of the market on Wednesday that its fourth quarter revenues more than doubled year over year, driven by 46 percent growth in commercial test volume and 34 percent growth in average insurance reimbursement per patient.2020-03-26View More
 
 - 
 - 
- 

 - 
HTG Molecular Diagnostics reported after the close of the market on Wednesday an 11 percent year-over-year drop in its full-year revenues, driven by a significant decrease in collaboration revenue.2020-03-26View More
 
 - 
 - 
- 

 - 
Quidel said after the close of the market on Wednesday that it has received expanded Emergency Use Authorization from the US Food and Drug Administration for the Lyra SARS-CoV-2 assay.2020-03-26View More
 
 - 
 - 
- 

 - 
The Association of the British Pharmaceutical Industry (ABPI) has issued a statement.2020-03-13View More
 
 - 
 - 
- 

 - 
Swift Biosciences has partnered with LGC Biosearch Technologies to incorporate Swift's targeted sequencing technology into LGC's kits and service offerings for the worldwide ag-bio market.2020-02-28View More
 
 - 
 - 
- 

 - 
Natera reported after the close of the market on Wednesday that its fourth quarter 2019 revenues grew 24 percent year over year.2020-02-28View More
 
 - 
 - 
- 

 - 
Swift Biosciences has partnered with LGC Biosearch Technologies to incorporate Swift's targeted sequencing technology into LGC's kits and service offerings for the worldwide ag-bio market.2020-02-28View More
 
 - 
 

- CAIVD WeChat
Subscription Account 

- CAIVD WeChat
Channels 
China Association of In-vitro Diagnostics
Part of the information in our website is from the internet.
If by any chance it violates your rights, please contact us.

